CNS-reactive B cells in the blood are biomarkers for therapeutic responsiveness and disease activity in Lemtrada-treated MS patients
- Conditions
- G35Multiple sclerosis
- Registration Number
- DRKS00015528
- Lead Sponsor
- Institut für Anatomie und ZellbiologieFAU Erlangen-Nürnberg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
RRMS, treatment with Lemtrada (Alemtuzumab)
Exclusion Criteria
Lack of compliance
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber of CNS-reactive B cells in the blood
- Secondary Outcome Measures
Name Time Method Treatment response to Lemtrada (Alemtuzumab)